Conversion of Community Marketing Authorisations (CAPs) to Great Britain Marketing Authorisations (MAs) - letter to industry
A letter providing guidance on the post-transition conversion process was sent by email on 23 October 2020 to the Community MA holders.
Documents
Details
Following the end of the transition period we will put in place arrangements for the continued authorisation of medicinal products. This letter was sent to inform you of the actions we intend to take concerning CAPs and the actions we need you to take as a Marketing Authorisation Holder (MAH) of a CAP.
If your company holds one or more Community MAs and has not received our letter, please email [email protected] so that we can verify the appropriate contact details.
For further information, please email our Customer Services Centre at [email protected]. You can also email [email protected] with urgent questions. Alternatively, contact your Trade Association by emailing:
- Association of the British Pharmaceutical Industry (ABPI): [email protected]
- British Generic Manufacturers Association (BGMA): [email protected]
- BioIndustry Association (BIA): [email protected]
- Clinical & Contract Research Association (CCRA): [email protected]
- Ethical Medicines Industry Group (EMIG): [email protected]
- Health Food Manufacturers’ Association (HFMA): [email protected]
- The National Pharmacy Association (NPA): [email protected]
- Proprietary Association of Great Britain (PAGB): [email protected]